Alkem Laboratories announced the launch of Ibuprofen and Famotidine tablets (800 mg/26.6 mg) in the United States, following an approval from the United States Food and Drug Administration (US FDA).
Ibuprofen and Famotidine tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC's Duexis tablets, 800 mg/26.6 mg.
This combination medication is used to relieve pain from rheumatoid arthritis and osteoarthritis while decreasing the risk of developing an ulcer from Ibuprofen use.
"This is the first generic approval of Duexis tablets, 800 mg/26.6 mg by the US FDA. The launch is a subject of ongoing litigation, the company said in a statement.
The announcement was made before market hours today, 4 August 2021.
Alkem Laboratories is a pharmaceutical company with global operations. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
The company's board will meet on 6 August 2021 to consider and approve financial results for the quarter ended on 30 June 2021.
The scrip is currently up 0.30% at Rs 3,520.15 on the BSE. In the past three months, the stock has gained 26.10% while the benchmark Sensex has added 12.28% during the same period.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
